Sun Pharma reports 9% sales growth, acquires Checkpoint Therapeutics
Sun Pharmaceutical Industries reported sales growth of 9% to Rs 520bn for FY25, with adjusted net profit rising 19% to Rs 119.8bn. EBITDA increased 17% to Rs 152.7bn, achieving a 29% margin.
The company maintained its position as India's largest pharma company with 8.3% market share. Innovative Therapies sales reached $1.2bn, driven by flagship product Ilumya at $681mn.
Sun Pharma announced the acquisition of Checkpoint Therapeutics Inc in 2025, enhancing its oncology portfolio.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Sun Pharmaceutical Industries publishes news
Free account required • Unsubscribe anytime